Mylan inc

Mylan Inc.: Pharmavitae Profile

Introduction
This analysis examines the historical and forecast performance for Mylan in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
valuable Point:
*Benchmark Mylan’s performance against key rivals in the prescription pharmaceutical sector
*Assess how the acquisition of Merck KGaA’s generics division will impact Mylan’s forecast performance
*Consider Mylan’s strategy to maintain its position as the world’s third largest generics company
Table of Contents :
ABOUT HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 7
Mylan: PharmaVitae forecasts at a glance 8
Strategic insight 9
1) 2002-06: Modest growth amid increasing US competition 10
2) 2007-09: M&A sustains position as third largest generics player 10
3) 2010-14: Profit growth via synergies and geographic expansion 11
SWOT analysis 13
Strengths 13
Weaknesses 14
Opportunities 14
Threats 14
Table of Contents 16
Table of figures 18
Chapter 3 Quarterly news update 19
Product developments 19
Deals and alliances 20
Product deals 20
M&A activity 21
Company announcements 22
Chapter 4 Company introduction 24
Key findings 24
Background 25
Key corporate developments 25
M&A history 25
Early M&A boosts branded Prescription pharmaceuticals capacity 26
Matrix acquisition provides API capabilities 26
Acquisition of Merck Generics 27
Mylan/Merck combination becomes third largest global generics player 27
The acquisition expands Mylan’s geographical presence 27
Acquisition of Merck KGaA’s CEE generics business 28
Mylan- potential for further M&A? 28
Current corporate structure 29
Generics Segment 29
Specialty Segment 29
Matrix Segment 30
Chapter 5 Company sales 31
Key findings 31
Prescription pharmaceutical sales and growth rate analysis, 2002-14 32
Product analysis 34
Product analysis, 2002-08 34
Product analysis, 2008-14 38
Therapy area analysis 42
Geographic analysis 45
Launch portfolio analysis 48
Launch analysis, 2008-14 48
Molecule type analysis 50
Externalization analysis 53
Chapter 6 Company financials 56
Key findings 56
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 57
Operating costs and profit analysis 58
Operating costs and profit analysis, 2002-08 59
Operating cost ratio and profit margin analysis, 2002-08 60
Operating cost ratio and profit margin analysis, 2008-14 61
Operating costs and profit analysis, 2008-14 63
Chapter 7 Key products and competitors 64
Overview 64
Central nervous system 65
EpiPen 65
Overview 65
Sales forecast 66
EpiPen sourced through Dey LP acquisition 66
Revenues affected by seasonal factors 66
Competition from Sciele’s TwinJect 66
Next generation device launched in October 2009 67
Respiratory 68
Perforomist 68
Overview 68
Sales forecast 69
Perforomist offers advantages over DuoNeb 69
Competition expected from Sepracor’s Brovana 69
DuoNeb 70
Overview 70
Sales forecast 71
DuoNeb to face declining sales over 2008-14 71
Oncology 72
gen. Xeloda 72
Mylan is forecast to launch a generic version of Roche’s Xeloda (capecitabine) in 2013. This launch date is based upon the patent expiry of the branded colon and breast cancer drug, however, should Mylan successfully challenge this patent protection, Mylan could launch gen. Xeloda at an earlier date. Mylan believes it is the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Xeloda and expects to qualify for 180 days of sole marketing exclusivity once final FDA approval is obtained. Roche filed a lawsuit on April 8 2009 alleging Mylan’s infringement of US patent no. 5,472,949. 72
Overview 72
Sales forecast 73
gen. Copaxone 74
Overview 74
Sales forecast 75
gen. Copaxone is product of Mylan’s alliance with NATCO Pharma 75
Manufacturing complexity will prove an obstacle 75
Sandoz/Momenta offering expected to be first generic to US market 76
gen. fentanyl 77
Overview 77
Sales forecast 78
Mylan owns the majority of the fentanyl patch market 78
Teva enters the Duragesic market in Q3 2008 78
Recall in 2008 expected to have a lasting impact on generic sales 78
gen. Depakote ER 80
Overview 80
Sales forecast 81
Depakote ER generic launched in 2009 81
Sales to decline post-2009 81
Chapter 8 Appendix 82
References 82
Abbreviations 82
Exchange rates 83
About84
About Healthcare 84
consulting 84
Disclaimer 86
For more information, please visit :
www.aarkstore.com/reports/Mylan-Inc-PharmaVitae-Profile-16847.html

Share and Enjoy:
  • Добавить ВКонтакте заметку об этой странице
  • Мой Мир
  • Facebook
  • Twitter
  • LiveJournal
  • MySpace
  • FriendFeed
  • В закладки Google
  • Google Buzz
  • Яндекс.Закладки
  • LinkedIn
  • Reddit
  • StumbleUpon
  • Technorati
  • Twitter
  • del.icio.us
  • Digg
  • БобрДобр
  • MisterWong.RU
  • Memori.ru
  • МоёМесто.ru
  • Сто закладок

Comments are closed.

Реклама
Recent Posts